News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Management Team Strengthened As Auspherix Drives New Class Of Antibacterials Towards The Clinic



11/17/2016 10:44:58 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Stevenage, UK – 17 November 2016 – Auspherix, the anti-infectives company meeting the urgent need for new antibiotics by developing a novel class of organogold antibacterials, today announced further strengthening of its Management team, with Dr Neil Miller transitioning to Chief Executive Officer (CEO) from Chief Scientific Officer (CSO), and the Company announcing two new appointments of Dr Richard Rutter as CSO and Dr Paul King as Head of Chemistry.

Dr Miller has served as CSO of Auspherix over the past 12 months, where he has been responsible for the Company’s antibiotic R&D programmes, having previously gained two decades of experience working at GlaxoSmithKline. In his role as CEO he will take on overall responsibility not only for driving Auspherix’s novel compounds through pre-clinical development and into the clinic, but also for extending the Company’s contacts with future potential investors and partners.

Auspherix Chairman Dr Roberto Solari said: “Neil has provided excellent hands-on scientific leadership as CSO. His proven expertise in drug discovery has been instrumental in focusing our R&D and driving our programmes forward. As CEO I am confident that he will continue to ensure scientific progress as well as to secure the finance and partnerships needed to give our innovative organogold antibiotics the best chance of success.”

In line with its R&D strategy, Auspherix has further strengthened its senior scientific team.

An expert pharmacologist and biologist with over 15 years of industry experience, Dr Rutter joins the Company as CSO with responsibility for leading and progressing its drug discovery programmes. Prior to his role at Auspherix, Richard was the Head of Biology at GlaxoSmithKline’s Neuroscience R&D Centre in Singapore. Previously, Richard was a Senior Research Biologist at Merck Sharpe and Dohme in the UK. Richard has a PhD in Molecular Neuroscience from the University of London, UK.

A medicinal chemist, Dr King joins Auspherix as Head of Chemistry bringing to the company over 15 years of experience in small-molecule drug discovery, working across multiple therapeutic areas. Prior to his appointment at Auspherix, Paul also held a number of positions at GlaxoSmithKline, including Team and Programme Leader in the Neural Pathways Discovery Performance Unit, Singapore. Paul has a PhD in Chemistry from Imperial College, UK and conducted post-doctoral research at the Scripps’ Research Institute, USA.

Welcoming Richard and Paul, Dr Neil Miller, CEO of Auspherix, said: “We believe our new class of organogold antibiotics has the potential to make a major contribution to the treatment of bacterial infections and are committed to diligently progressing our antibacterial pipeline, in order to help address the worldwide healthcare crisis of rising antibiotic resistance and the need to expand the repertoire treatment options. Auspherix will greatly benefit from the expertise that Richard and Paul bring to the Company.”

- ENDS -

Notes to Editors

About Auspherix Ltd

Auspherix Ltd has discovered a novel class of antibacterials based on its proprietary organogold chemistry platform. Its compound series show activity against a broad range of important Gram-negative and Gram-positive bacteria, including multidrug resistant (MDR) clinical isolates, with profiles consistent with their use as antibiotics in a number of indications with high unmet need and large market potential.

Based in Stevenage UK (in the Stevenage Bioscience Catalyst facility), the Company was founded in late 2013 based on discoveries made at the ithree institute at the University of Technology Sydney (UTS). The Company has raised AUS $2million in Seed investments (2013-2014) from Australia’s Medical Research Commercialisation Fund (MRCF) and £6 million in Series A round (2015) from the MRCF and the UK’s Imperial innovations plc (AIM IVO).

For further information please visit www.auspherix.com

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES